Celldex Therapeutics
Develops KIT and bispecific antibodies for mast-cell-driven inflammatory diseases.
Something off on this page? Send us feedback.
Profile
Develops barzolvolimab, a late-stage KIT antibody for spontaneous and inducible urticarias, alongside the early-stage TSLP/SCF bispecific CDX-622. The clinical-stage model has no approved products and concentrates development spending on barzolvolimab.
Develops antibody therapies for mast-cell-driven allergic, inflammatory and autoimmune diseases. Barzolvolimab, a KIT-targeted monoclonal antibody, is in global late-stage studies for chronic spontaneous urticaria, cold urticaria and symptomatic dermographism, while a mid-stage atopic dermatitis study continues. Work in prurigo nodularis was discontinued after missing key efficacy objectives.
Extends its mast-cell platform with CDX-622, a bispecific antibody designed to neutralize TSLP and soluble stem cell factor. Early clinical work spans healthy volunteers and asthma, with expansion planned in allergic rhinitis and food allergy.
Operates as a single reportable segment and has no approved products or product revenue. Research spending is concentrated on barzolvolimab; progress depends on clinical results, regulatory approval, manufacturing and commercialization readiness, and continued financing.
Company facts
Key statistics
Year to date +44.7% · Average volume (30d) 901.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Barclays | Reiterate | Overweight | $48 | $53 |
| Jul 29, 2026 | Wells Fargo | Reiterate | Overweight | $48 | $72 |
| Jul 22, 2026 | Cantor Fitzgerald | Reiterate | Overweight | $61 | |
| Jul 22, 2026 | Wells Fargo | Reiterate | Overweight | $54 | $48 |
| Jul 22, 2026 | Morgan Stanley | Reiterate | Overweight | $46 | $40 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$1.06 | −$0.94 | +11.3% | $734.9K | $22.0K | −97.0% | +0.36% |
| May 7, 2026Q1 FY26 | −$1.15 | −$1.18 | −2.9% | $795.4K | $15.0K | −98.1% | +1.95% |
| Feb 25, 2026Q4 FY25 | −$1.00 | −$1.22 | −22.0% | $1.3M | $100.0K | −92.4% | −0.58% |
| Nov 10, 2025Q3 FY25 | −$0.88 | −$1.01 | −14.8% | $1.5M | — | — | +7.50% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $695.0K | $730.0K | $0 | $75.0K | $15.0K | $22.0K | |
| Gross profit | −$51.9M | −$53.5M | −$62.9M | $75.0K | −$839.0K | $22.0K | |
| Operating income | −$62.7M | −$63.9M | −$73.6M | −$87.2M | −$84.4M | −$80.6M | |
| Net income | −$53.8M | −$56.6M | −$67.0M | −$81.4M | −$78.7M | −$73.5M | |
| Diluted EPS | −$0.81 | −$0.85 | −$1.01 | −$1.23 | −$1.18 | −$0.94 | |
| Gross margin | -7,470.4% | -7,324.1% | — | 100.0% | -5,593.3% | 100.0% | |
| Operating margin | -9,027.2% | -8,747.5% | — | -116,249.3% | -562,900.0% | -366,468.2% |
Fiscal years (4-quarter sums)FY21 $4.7M · FY22 $2.4M · FY23 $6.9M · FY24 $7.0M · FY25 $1.5M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $717.6M · Total debt $4.9M · Total assets $782.3M · Shareholders' equity $714.6M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 66.54M · Float 61.34M · 92.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Wellington Management Group LLP | 9.54M | 14.34% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 7.00M | 10.52% | 13F | Aug 7, 2026 |
| Kynam Capital Management, LP | 5.32M | 8.00% | 13F | Aug 14, 2026 |
| T. Rowe Price Associates, Inc. | 4.69M | 6.00% | 13G | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 4.69M | 7.04% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 4, 2025 | Freddy A. Jimenez | officer: SVP & GENERAL COUNSEL | −4,166 | $29.10 |
| Nov 13, 2025 | Richard M. Wright | other: Former Officer | −49,298 | $24.00 |
Peers
- Novartis (ADR)
CSU pressure from Xolair and remibrutinib.
- Sanofi (ADR)
Dupixent and rilzabrutinib span CSU and inflammatory skin.
- Regeneron
Dupixent franchise overlaps CSU, PN, AD and asthma.
- Jasper Therapeutics
Anti-KIT CSU program mirrors barzolvolimab most directly.
- Incyte
Povorcitinib offers an oral CSU alternative.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | $39.12 | +0.08% | $2.60B | — | — | 23,240.9 | −97.0% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| Jasper Therapeutics | $0.7140 | +3.02% | $11.4M | — | — | — | — |
| Incyte | $124.37 | −0.03% | $25.21B | 15.8 | 43.0 | 4.3 | +37.7% |
| Median | 21.4 | 16.4 | 4.8 | +14.0% |